Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Neuropharmacology

• Publication date

  2000-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0028-3908(00)00044-7PMID 10818253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of the Stress Response by Corticotropin-Releasing Factor Receptors

  2000cited by this paper
• Neuroendocrinology in Physiology and Medicine

  2000cited by this paper
• The ligand‐selective Domains of Corticotropin‐Releasing Factor Type 1 and Type 2 Receptor Reside in Different Extracellular Domains

  1999cited by this paper
• The role of corticotropin-releasing factor in depression and anxiety disorders.

  1999cited by this paper
• N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants

  1999cited by this paper
• Human CRF2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay

  1999cited by this paper
• Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.

  1999cited by this paper
• Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates.

  1999cited by this paper
• Isolation and Pharmacological Characterization of Two Functional Splice Variants of Corticotropin‐Releasing Factor Type 2 Receptor from Tupaia belangeri

  1999cited by this paper
• Identification of Amino Acids in the N‐Terminal Domain of Corticotropin‐Releasing Factor Receptor 1 that Are Important Determinants of High‐Affinity Ligand Binding

  1999cited by this paper
• Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.

  1999cited by this paper
• 7TM receptors: the splicing on the cake.

  1999cited by this paper
• Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists.

  1999cited by this paper
• RNA editing of brain glutamate receptor channels: mechanism and physiology.

  1998cited by this paper
• Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.

  1998cited by this paper
• Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor.

  1998cited by this paper
• Corticotropin-releasing factor receptor type 1 from Tupaia belangeri--cloning, functional expression and tissue distribution.

  1998cited by this paper
• The genomic organization of the human corticotropin-releasing factor type-1 receptor.

  1998cited by this paper
• Identification of Two Corticotropin‐Releasing Factor Receptors from Xenopus laevis with High Ligand Selectivity: Unusual Pharmacology of the Type 1 Receptor

  1997cited by this paper
• Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach.

  1997cited by this paper
• Regulation of Corticotropin‐Releasing Factor Receptor Function in Human Y‐79 Retinoblastoma Cells: Rapid and Reversible Homologous Desensitization but Prolonged Recovery

  1997cited by this paper
• The Genomic Structure of the Rat Corticotropin Releasing Factor Receptor

  1996cited by this paper
• Cloning and characterization of human urocortin.

  1996cited by this paper
• Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid.

  1996cited by this paper
• Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.

  1995cited by this paper
• Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?

  1990cited by this paper
• Scintillation proximity assay: a sensitive and continuous isotopic method for monitoring ligand/receptor and antigen/antibody interactions.

  1987cited by this paper

• Corticotropin-releasing factor receptors in GtoPdb v.2025.3

  2025cites this paper
• Corticotropin-releasing factor receptors in GtoPdb v.2023.1

  2023influential citation
• Corticotropin-releasing factor receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019influential citation
• Assays of Obesity-Regulating Peptide Hormones

  2014cites this paper
• Urocortin 2 treatment is protective in excitotoxic retinal degeneration.

  2014cites this paper
• Neuropeptides and diabetic retinopathy

  2013cites this paper
• Application of Scintillation Proximity Assay in Drug Discovery

  2012cites this paper
• Members of CRF family and their receptors: from past to future.

  2011cites this paper
• Novel Neuroprotective Strategies in Ischemic Retinal Lesions

  2010cites this paper
• The involvement of central corticotropin-releasing hormone and its receptors in sleep-wake regulation of mice

  2010cites this paper
• Urocortin 2 protects against retinal degeneration following bilateral common carotid artery occlusion in the rat.

  2009cites this paper
• CRF-2 Corticotropin-Releasing Factor Receptor

  2008cites this paper
• Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

  2006cites this paper
• Urocortins of the South African clawed frog, Xenopus laevis: conservation of structure and function in tetrapod evolution.

  2005cites this paper
• Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist.

  2005cites this paper
• Irreversible Binding Kinetics of Neuropeptide Y Ligands to Y2 but Not to Y1 and Y5 Receptors

  2005cites this paper
• Molecular regulation of the CRF system

  2005cites this paper
• Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells.

  2004cites this paper
• Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant.

  2004cites this paper
• Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.

  2004cites this paper
• International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands

  2003influential citation
• Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep.

  2002cites this paper
• Design, synthesis and pharmacological characterization of new highly selective CRF(2) antagonists: development of 123I-K31440 as a potential SPECT ligand.

  2002cites this paper
• The highly selective CRF2 receptor antagonist K41498 binds to presynaptic CRF2 receptors in rat brain

  2002cites this paper
• The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.

  2002cites this paper
• Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart.

  2002cites this paper
• Anti-obesity activity 1

  2002cites this paper
• Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.

  2001influential citation
• Molecular biology of the CRH receptors-- in the mood.

  2001cites this paper
• Chapter 3. New developments in the study of corticotropin releasing factor

  2001cites this paper
• 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors.

  2001cites this paper
• Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo.

  2001cites this paper
• International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands

  year unknowncites this paper